Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

OBJECTIVE: To use the large dataset from the Tysabri Outreach: Unified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard interval dosing (SID) in patients with multiple sclerosis (MS). MET...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurology
Main Authors: Ryerson, Lana Zhovtis, Foley, John, Chang, Ih, Kister, Ilya, Cutter, Gary, Metzger, Ryan R., Goldberg, Judith D., Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Kasliwal, Rachna, Ren, Zheng, Hotermans, Christophe, Ho, Pei-Ran, Campbell, Nolan
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7010325/
https://ncbi.nlm.nih.gov/pubmed/31515290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000008243
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados